EradicAide HIV vaccine regulatory update

The University of Texas received European Patent No. 0671947 covering antiviral vaccines that elicit cytotoxic T lymphocyte (CTL) responses without eliciting an antibody response. BQST, the exclusive licensee of the patent, is developing its EradicAide vaccine based on the technology in collaboration with Biovector Therapeutics S.A. (Toulouse, France) (see BioCentury, April 17). ...